The company's underlying profit did, however, increase.

Profit for the group grew 10 per cent, despite a dip in revenue.

The pharmaceutical and animal health products maker posted a 4.9 per cent gain in profit.

Other markets don't fare so well after fall in oil price.

A2 Milk stock falls as firm's CEO and chair sell shares.

Ebos Group's recent acquisitions helped the pharmaceutical and animal health products maker lift first-half profit 7.2 per cent.

This NZX-listed healthcare distributor has gone through a meteoric phase of growth, completing roughly 20 acquisitions over the past 10 years.

Ebos Group will expand its involvement with natural health products after agreeing to buy New Zealand vitamin and herbal tea maker Red Seal for $80 million.

Ebos Group, the healthcare and animal care products company, posted a 15 per cent gain in full-year profit, led by increased sales and an improved margin from its Australian healthcare businesses.

Ebos GroupTurnover at medical consumable and pharmaceutical products company Ebos Group has grown from around $8 million to $6 billion in the 27 years since Mark Waller became CEO.

When Mark Waller took over the top job at listed healthcare supplier Ebos, he never imagined he'd be dropping the reins 27 years later.

What are the top 10 worst performing shares of 2014 so far? Find out with a graphic showing the biggest losers.

The NZX will run out of steam unless companies, particularly the larger ones, can take advantage of the stronger economy, writes Brian Gaynor.

Ebos Group's $1.1 billion acquisition of Australian firm Symbion this week again highlighted an ongoing issue with getting independent research on NZX-listed companies.

Normalising profits to bury the bottom line shouldn't be the norm.